Edoxaban, an oral direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro

被引：0
|
作者：
Morishima, Y. [1 ]
Honda, Y. [1 ]
Kamisato, C. [1 ]
机构：
[1] Daiichi Sankyo Co Ltd, Tokyo, Japan
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2013年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：688 / 688
页数：1
相关论文
共 50 条
  • [21] Melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, nor heparin aggravates tissue factor-induced hypercoagulation in rats
    Furugohri, Taketoshi
    Fukuda, Toshio
    Tsuji, Naoki
    Kita, Akemi
    Morishima, Yoshiyuki
    Shibano, Toshiro
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2012, 686 (1-3) : 74 - 80
  • [22] Effects of Food on the Pharmacokinetics of Edoxaban, an Oral Direct Factor Xa Inhibitor, in Healthy Volunteers
    Mendell, Jeanne
    Tachibana, Masaya
    Shi, Minggao
    Kunitada, Satoshi
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (05): : 687 - 694
  • [23] Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents
    Fukuda, Toshio
    Honda, Yuko
    Kamisato, Chikako
    Morishima, Yoshiyuki
    Shibano, Toshiro
    THROMBOSIS AND HAEMOSTASIS, 2012, 107 (02) : 253 - 259
  • [24] Impaired carboxylation of osteocalcin by warfarin, but not edoxaban, an oral direct factor Xa inhibitor, in rats
    Morishima, Y.
    Kamisato, C.
    Honda, Y.
    Furugohri, T.
    Shibano, T.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 135 - 136
  • [25] Effect of SanOrg123781A, a synthetic hexadecasaccharide, on clot-bound thrombin and factor Xa in vitro and in vivo
    Hérault, JP
    Cappelle, M
    Bernat, A
    Millet, L
    Bono, F
    Schaeffer, P
    Herbert, JM
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (09) : 1959 - 1965
  • [26] Tissue factor pathway inhibitor (TFPI) and a direct factor Xa inhibitor (DX-9065a) but not a glycoprotein IIb/IIIa inhibitor (ReoPro(R)) antagonize platelet activation induced by factor Xa and tissue factor.
    Kaiser, B
    Jeske, WP
    Walenga, JM
    Fareed, J
    BLOOD, 1997, 90 (10) : 3012 - 3012
  • [27] Direct factor Xa inhibitor edoxaban: from bench to clinical practice
    Brekelmans, M. P. A.
    Middeldorp, S.
    Coppens, M.
    EXPERT REVIEW OF HEMATOLOGY, 2015, 8 (06) : 707 - 725
  • [28] The effect of the oral direct factor Xa inhibitor rivaroxaban on tissue factor mediated in vitro platelet aggregation is enhanced by a P2Y12 receptor blocker
    Perzborn, E.
    Harwardt, M.
    Heitmeier, S.
    Laux, V
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 74 - 74
  • [29] Assessment of factor Xa chromogenic assays for measuring the pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor
    Perzborn, E.
    Hardwardt, M.
    Samama, M. M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 379 - 380
  • [30] Evaluation of the oral direct factor Xa inhibitor - betrixaban
    Palladino, Michael
    Merli, Geno
    Thomson, Lynda
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (11) : 1465 - 1472
12345